Market Introduction
The U.S. Point-of-Care (PoC) diagnostics market is witnessing robust growth, valued at USD 9.69 billion in 2024 and projected to reach USD 18.83 billion by 2034, expanding at a CAGR of 6.88% from 2025 to 2034. The rising prevalence of chronic illnesses, infectious diseases, and growing demand for rapid diagnostics are fueling the market. PoC diagnostics allow on-site testing, delivering immediate results to inform timely medical decisions, improving patient care, and optimizing hospital resources.
For detailed market analysis, trends, and competitive landscape, visit U.S. Point-of-Care Diagnostics Market.
PoC testing is gaining momentum due to biomarker detection, decentralized testing, clinical point-of-care devices, and home-based diagnostics, which together enhance healthcare efficiency and patient outcomes.
Market Overview
The U.S. PoC diagnostics market benefits from technological advancements, increasing patient awareness, and demand for faster, accurate test results. Hospitals, clinics, and home healthcare providers are increasingly adopting compact and automated PoC devices for a variety of diagnostic applications.
The market is supported by:
- Healthcare digitization integrating PoC results into electronic health records.
- Rising preventive healthcare initiatives that leverage rapid testing.
- Expansion of home-based diagnostics for chronic conditions like diabetes and cardiovascular diseases.
Market Segmentation
By Product Type
- Hematology Analyzers – Blood count and coagulation testing.
- Biochemistry Analyzers – Metabolic and electrolyte assessment.
- Immunoassays – Rapid detection of infectious and non-infectious biomarkers.
- Molecular Diagnostics – PCR and isothermal amplification for pathogens.
- Blood Glucose Monitoring Devices – Diabetes management at clinics and homes.
- – Kidney function and infection screening.
By Technology
- Lateral Flow Assays (LFAs) – Rapid, low-cost diagnostic solutions.
- Microfluidic Platforms – Multiplexing and high-sensitivity testing.
- – Molecular PoC testing for pathogen detection.
- – Used in biomarker and metabolic monitoring.
By Application
- Cardiovascular Testing – Troponin, BNP, CRP, and lipid panels.
- Diabetes Monitoring – Glucose, HbA1c, and continuous monitoring devices.
- Infectious Disease Testing – COVID-19, influenza, HIV, hepatitis, and other pathogens.
- Oncology Testing – Rapid detection of cancer biomarkers.
- Other Applications – Pregnancy, fertility, and wellness diagnostics.
By End-User
- Diagnostic Laboratories
- Home Healthcare
By Distribution Channel
- Direct Sales – Hospitals and healthcare networks
- Medical Device Distributors – Broad reach in clinics and labs
- Online Channels – Increasing for home diagnostics and self-testing kits
Regional Insights
Regional adoption in the U.S. varies based on healthcare access, technological adoption, and disease prevalence:
- Northeast – High uptake due to advanced hospital systems and healthcare technology centers.
- Midwest – Increasing PoC adoption in community and rural hospitals.
- South – Rising prevalence of chronic diseases drives demand for PoC tests.
- West Coast – Urban hospitals adopting advanced PoC devices and integrated digital solutions.
Urban centers dominate due to better healthcare infrastructure and higher patient awareness.
Market Drivers
- Increasing Chronic and Infectious Disease Burden
- Diabetes, cardiovascular disorders, and infectious diseases drive demand for rapid PoC diagnostics.
- Compact, automated, and high-sensitivity devices improve patient care efficiency.
- Shifting diagnostic services from central labs to bedside or home-based testing improves accessibility.
- Blood glucose monitors, infectious disease kits, and chronic disease monitoring tools drive market expansion.
- PoC devices connected with mobile apps and EHRs allow real-time monitoring and remote patient management.
Market Challenges
- High costs of advanced PoC devices and consumables.
- Regulatory approvals and compliance requirements affecting device launches.
- Competition with centralized laboratory testing for certain diagnostic needs.
- Insurance coverage and reimbursement issues limiting adoption.
Competitive Landscape
The U.S. PoC diagnostics market is competitive, with companies investing in .
Key Companies:
- Abbott Laboratories
- Roche Diagnostics
- Siemens Healthineers
- Beckman Coulter
- Quidel Corporation
- Becton, Dickinson and Company (BD)
- BioMérieux
- Cepheid (Danaher Corporation)
- Hologic, Inc.
- OraSure Technologies
Focus areas include miniaturized PoC devices, molecular diagnostics, rapid immunoassays, and digital health integration.
Market Trends
- Rapid Diagnostics Expansion – Fast-turnaround tests for emergency care and outpatient services.
- Integration with Digital Health Platforms – EHR connectivity and telemedicine integration.
- Home Healthcare and Self-Testing – Increasing adoption of PoC devices at home.
- Multiplex Testing Platforms – Detection of multiple biomarkers simultaneously for efficiency.
Future Outlook
The U.S. PoC diagnostics market is expected to grow due to:
- Rising adoption of rapid diagnostic and home-based testing devices.
- Expansion of telehealth and remote patient monitoring services.
- Technological advancements in molecular PoC testing and miniaturized platforms.
- Increasing use in preventive healthcare, chronic disease monitoring, and infectious disease detection.
Miniaturization, automation, and digital connectivity will continue to transform PoC diagnostics, making testing faster, more accurate, and accessible across healthcare settings.
Conclusion
The U.S. Point-of-Care diagnostics market is projected to reach USD 18.83 billion by 2034, growing at a CAGR of 6.88%. Growth is driven by rapid diagnostics, decentralized testing, clinical point-of-care solutions, and PoC devices. The adoption of home healthcare testing, integration with digital health platforms, and technological innovations will continue to propel market expansion. For updated insights, visit U.S. Point-of-Care diagnostics.
More Trending Latest Reports By Polaris Market Research:
Automotive Operating System Market
Alport Syndrome Treatment Market
North America SGLT2 Inhibitors Market
Automotive E-Compressor Market
